Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2015

Equity related disclosures

Schedule of stock option activity

	2013					2014
	Options			Weighted Average Exercise Price		Options			Weighted Average Exercise Price
Outstanding, beginning of period		4,268,240		$	44.35		4,010,146		$	47.23
Granted		1,047,133			53.18		769,636			59.62
Forfeited		(165,734	)		49.66		(267,028	)		53.74
Exercised		(1,139,493	)		41.53		(1,191,691	)		44.45
Outstanding, end of period		4,010,146			47.23		3,321,063			50.58

	2015
	Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding, beginning of period		3,321,063		$	50.58
Granted		1,004,321			62.65
Forfeited		(244,658	)		60.25
Exercised		(1,140,886	)		47.41
Outstanding, end of period		2,939,840		$	55.13		7.14	$	20,858
Vested and expected to vest at end of period		2,910,000		$	55.07		7.12	$	20,794
Exercisable, end of period		1,431,732		$	50.18		5.55	$	16,529

Schedule of weighted average assumptions used to determine weighted average grant date fair value

	2013			2014			2015
Risk-free interest rate		0.67	%		1.16	%		1.28	%
Expected life		4 years			4 years			4 years
Expected volatility		27.86	%		26.20	%		25.03	%
Expected dividend yield		0.00	%		0.00	%		0.00	%

Schedule of nonvested restricted stock award activity

	2013					2014					2015
	Shares			Weighted Average Grant Date Fair Value		Shares			Weighted Average Grant Date Fair Value		Shares			Weighted Average Grant Date Fair Value
Outstanding, beginning of period		23,672		$	42.25		192,165		$	56.59		1,626,827		$	57.66
Awarded(1)		192,165			56.59		1,451,231			57.75		20,115			67.12
Vested		(23,672	)		42.25		(16,569	)		52.82		(537,320	)		57.56
Forfeited		—			—		—			—		—			—
Outstanding, ending of period		192,165			56.59		1,626,827			57.66		1,109,622			57.88

(1)           December 31, 2013 includes 175,596 shares associated with the Partners Rx acquisition. December 31, 2014 includes 1,433,946 shares associated with the CDMI acquisition.

Schedule of Non vested restricted stock units

	2013					2014					2015
	Shares			Weighted Average Grant Date Fair Value		Shares			Weighted Average Grant Date Fair Value		Shares			Weighted Average Grant Date Fair Value
Outstanding, beginning of period		202,690		$	47.38		194,913		$	50.21		156,695		$	54.88
Awarded		98,580			52.62		76,306			60.39		187,272			63.42
Vested		(95,138	)		56.72		(91,510	)		49.53		(79,036	)		52.82
Forfeited		(11,219	)		49.79		(23,014	)		54.86		(33,843	)		61.54
Outstanding, ending of period		194,913			50.21		156,695			54.88		231,088			61.53

Computation of basic and diluted earnings (loss) per share

        The following table reconciles income (numerator) and shares (denominator) used in the Company's computations of net income per share for the years ended December 31, 2013, 2014 and 2015 (in thousands, except per share data):

	2013		2014		2015
Numerator:
Net income attributable to Magellan Health, Inc.	$	125,261	$	79,404	$	31,413
Denominator:
Weighted average number of common shares outstanding—basic		27,054		26,689		24,865
Common stock equivalents—stock options		564		495		316
Common stock equivalents—RSAs		13		155		626
Common stock equivalents—RSUs		42		14		33
Common stock equivalents—PSUs		—		—		35
Common stock equivalents—employee stock purchase plan		2		2		2
Weighted average number of common shares outstanding—diluted		27,675		27,355		25,877
Net income attributable to Magellan Health, Inc. per common share—basic	$	4.63	$	2.98	$	1.26
Net income attributable to Magellan Health, Inc. per common share—diluted	$	4.53	$	2.90	$	1.21

October 2011 Share Repurchase Program

Equity related disclosures

Schedule of stock repurchases made under open market

Pursuant to this program, the Company made purchases as follows (aggregate cost excludes broker commissions and is reflected in millions):

Period	Total Number of Shares Purchased		Average Price Paid per Share		Aggregate Cost
November 11, 2011 - December 31, 2011		671,776	$	48.72	$	32.7
January 1, 2012 - December 31, 2012		459,252		50.27		23.1
January 1, 2013 - December 31, 2013		1,159,871		51.83		60.1
January 1, 2014 - November 21, 2014		3,183,306		57.82		184.1
		5,474,205			$	300.0

October 2014 Share Repurchase Program

Equity related disclosures

Schedule of stock repurchases made under open market

Pursuant to this program, the Company made purchases as follows (aggregate cost excludes broker commissions and is reflected in millions):

Period	Total Number of Shares Purchased		Average Price Paid per Share		Aggregate Cost
November 24, 2014 - December 31, 2014		232,170	$	60.65	$	14.1
January 1, 2015 - October 21, 2015		3,153,156		58.96		185.9
		3,385,326			$	200.0

October 2015 Share Repurchase Program

Equity related disclosures

Schedule of stock repurchases made under open market

Pursuant to this program, the Company made purchases as follows (aggregate cost excludes broker commissions and is reflected in millions):

Period	Total Number of Shares Purchased		Average Price Paid per Share		Aggregate Cost
October 26, 2015 - December 31, 2015		345,044	$	53.46	$	18.4
		345,044			$	18.4